SEMA5B

Across TCGA pan-cancer cohorts, SEMA5B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SEMA5B data layer compared with 22 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher SEMA5B Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated SEMA5B expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

STAD, UCEC, and COAD are the cancer types where SEMA5B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Median	III,IV	0.810	0.325	.028	8	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
COAD	OS	Median	III,IV	0.281	0.715	.002	6	view →
HNSC	OS	Median	All	0.293	0.608	.026	3	view →
LIHC	DFS	Median	II,III,IV	0.044	0.414	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SEMA5B–STAD (DFS)

Open the STAD breakdown →